Abstract
Tuberculosis (TB) is a deadly infectious disease of humans caused by Mycobacterium tuberculosis (Mtb). In 2016, there were about 10 million new cases and 1.8 million deaths attributed to TB worldwide (WHO Report 2017). In addition, about a third of the world population has asymptomatic latent Mtb infection (LTBI), of which about 10% can reactivate to symptomatic active TB in their lifetime dependent upon their immune status. However, in a population, Mtb infection results in a heterogeneous outcome, ranging from complete bacterial clearance to the establishment of LTBI or development of a full-blown disease. A key feature of TB pathogenesis is granuloma formation, which has been a subject of intense research for several decades. Although granulomas are thought to protect the host by containing Mtb in a confined area and preventing bacterial dissemination to other parts of the body, it is also likely to act as a safe-harbor for the infecting bacteria to thrive and persist in a niche with a compromised immunity. This chapter summarizes various cellular events underlying TB pathogenesis and the role of different types of immune cells involved in granuloma formation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abe, Y., Nakamura, M., Oshika, Y., Hatanaka, H., Tokunaga, T., Ohkubo, Y., et al. (2001). Serum levels of vascular endothelial growth factor and cavity formation in active pulmonary tuberculosis. Respiration, 68(5), 496–500.
Agostini, C., Cassatella, M., Zambello, R., Trentin, L., Gasperini, S., Perin, A., et al. (1998). Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. Journal of Immunology, 161(11), 6413–6420.
Akira, S., Uematsu, S., & Takeuchi, O. (2006). Pathogen recognition and innate immunity. Cell, 124(4), 783–801.
Alcais, A., Fieschi, C., Abel, L., & Casanova, J. L. (2005). Tuberculosis in children and adults: Two distinct genetic diseases. The Journal of Experimental Medicine, 202(12), 1617–1621.
Algood, H. M., Chan, J., & Flynn, J. L. (2003). Chemokines and tuberculosis. Cytokine & Growth Factor Reviews, 14(6), 467–477.
Almeida Cde, S., Abramo, C., Alves, C. C., Mazzoccoli, L., Ferreira, A. P., & Teixeira, H. C. (2009). Anti-mycobacterial treatment reduces high plasma levels of CXC-chemokines detected in active tuberculosis by cytometric bead array. Memórias do Instituto Oswaldo Cruz, 104(7), 1039–1041.
Aronis, K. N., Chamberland, J. P., & Mantzoros, C. S. (2013). GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism, 62(9), 1279–1286.
Bafica, A., Scanga, C. A., Feng, C. G., Leifer, C., Cheever, A., & Sher, A. (2005). TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. The Journal of Experimental Medicine, 202(12), 1715–1724.
Balu, S., Reljic, R., Lewis, M. J., Pleass, R. J., McIntosh, R., van Kooten, C., et al. (2011). A novel human IgA monoclonal antibody protects against tuberculosis. Journal of Immunology, 186(5), 3113–3119.
Bao, Y., Liu, X., Han, C., Xu, S., Xie, B., Zhang, Q., et al. (2014). Identification of IFN-gamma- producing innate B cells. Cell Research, 24(2), 161–176.
Benator, D., Bhattacharya, M., Bozeman, L., Burman, W., Cantazaro, A., Chaisson, R., et al. (2002). Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: A randomised clinical trial. Lancet, 360(9332), 528–534.
Berry, M. P., Graham, C. M., McNab, F. W., Xu, Z., Bloch, S. A., Oni, T., et al. (2010). An interferon- inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature, 466(7309), 973–977.
Bezuidenhout, J., Roberts, T., Muller, L., van Helden, P., & Walzl, G. (2009). Pleural tuberculosis in patients with early HIV infection is associated with increased TNF-alpha expression and necrosis in granulomas. PLoS One, 4(1), e4228.
Bhatt, K., & Salgame, P. (2007). Host innate immune response to Mycobacterium tuberculosis. Journal of Clinical Immunology, 27(4), 347–362.
Bodnar, K. A., Serbina, N. V., & Flynn, J. L. (2001). Fate of Mycobacterium tuberculosis within murine dendritic cells. Infection and Immunity, 69(2), 800–809.
Boisson-Dupuis, S., El Baghdadi, J., Parvaneh, N., Bousfiha, A., Bustamante, J., Feinberg, J., et al. (2011). IL-12Rbeta1 deficiency in two of fifty children with severe tuberculosis from Iran, Morocco, and Turkey. PLoS One, 6(4), e18524.
Bonecini-Almeida, M. G., Ho, J. L., Boechat, N., Huard, R. C., Chitale, S., Doo, H., et al. (2004). Down- modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis. Infection and Immunity, 72(5), 2628–2634.
Boselli, D., Losana, G., Bernabei, P., Bosisio, D., Drysdale, P., Kiessling, R., et al. (2007). IFN- gamma regulates Fas ligand expression in human CD4+ T lymphocytes and controls their anti-mycobacterial cytotoxic functions. European Journal of Immunology, 37(8), 2196–2204.
Bourigault, M. L., Vacher, R., Rose, S., Olleros, M. L., Janssens, J. P., Quesniaux, V. F., et al. (2013). Tumor necrosis factor neutralization combined with chemotherapy enhances Mycobacterium tuberculosis clearance and reduces lung pathology. American Journal of Clinical and Experimental Immunology, 2(1), 124–134.
Bowdish, D. M., Sakamoto, K., Kim, M. J., Kroos, M., Mukhopadhyay, S., Leifer, C. A., et al. (2009). MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis. PLoS Pathogens, 5(6), e1000474.
Bulut, Y., Michelsen, K. S., Hayrapetian, L., Naiki, Y., Spallek, R., Singh, M., et al. (2005). Mycobacterium tuberculosis heat shock proteins use diverse toll-like receptor pathways to activate pro-inflammatory signals. The Journal of Biological Chemistry, 280(22), 20961–20967.
Cadena, A. M., Fortune, S. M., & Flynn, J. L. (2017). Heterogeneity in tuberculosis. Nature Reviews. Immunology, 17(11), 691–702.
Carmona, J., Cruz, A., Moreira-Teixeira, L., Sousa, C., Sousa, J., Osorio, N. S., et al. (2013). Mycobacterium tuberculosis strains are differentially recognized by TLRs with an impact on the immune response. PLoS One, 8(6), e67277.
Cassatella, M. A., Gasperini, S., Bovolenta, C., Calzetti, F., Vollebregt, M., Scapini, P., et al. (1999). Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: Evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood, 94(8), 2880–2889.
Chakravarty, S. D., Zhu, G., Tsai, M. C., Mohan, V. P., Marino, S., Kirschner, D. E., et al. (2008). Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infection and Immunity, 76(3), 916–926.
Chan, J., Mehta, S., Bharrhan, S., Chen, Y., Achkar, J. M., Casadevall, A., et al. (2014). The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Seminars in Immunology, 26(6), 588–600.
Chatterjee, S. B., Dey, S., Shi, W. Y., Thomas, K., & Hutchins, G. M. (1997). Accumulation of glycosphingolipids in human atherosclerotic plaque and unaffected aorta tissues. Glycobiology, 7(1), 57–65.
Collins, H. L., & Kaufmann, S. H. (2001). The many faces of host responses to tuberculosis. Immunology, 103(1), 1–9.
Condos, R., Rom, W. N., Liu, Y. M., & Schluger, N. W. (1998). Local immune responses correlate with presentation and outcome in tuberculosis. American Journal of Respiratory and Critical Care Medicine, 157(3 Pt 1), 729–735.
Cooper, A. M. (2009). Cell-mediated immune responses in tuberculosis. Annual Review of Immunology, 27, 393–422.
Cooper, A. M., Mayer-Barber, K. D., & Sher, A. (2011). Role of innate cytokines in mycobacterial infection. Mucosal Immunology, 4(3), 252–260.
Cruz, A., Fraga, A. G., Fountain, J. J., Rangel-Moreno, J., Torrado, E., Saraiva, M., et al. (2010). Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. The Journal of Experimental Medicine, 207(8), 1609–1616.
Cun, X., Xie, J., Lin, S., Fu, N., Deng, S., Xie, Q., et al. (2015). Gene profile of soluble growth factors involved in angiogenesis, in an adipose-derived stromal cell/endothelial cell co-culture, 3D gel model. Cell Proliferation, 48(4), 405–412.
Dang, E. V., Barbi, J., Yang, H. Y., Jinasena, D., Yu, H., Zheng, Y., et al. (2011). Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell, 146(5), 772–784.
Daniel, T. M., Oxtoby, M. J., Pinto, E., & Moreno, E. (1981). The immune spectrum in patients with pulmonary tuberculosis. The American Review of Respiratory Disease, 123(5), 556–559.
Daniel, J., Maamar, H., Deb, C., Sirakova, T. D., & Kolattukudy, P. E. (2011). Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathogens, 7(6), e1002093.
Datta, M., Via, L. E., Kamoun, W. S., Liu, C., Chen, W., Seano, G., et al. (2015). Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proceedings of the National Academy of Sciences of the United States of America, 112(6), 1827–1832.
Davis, J. M., & Ramakrishnan, L. (2009). The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell, 136(1), 37–49.
de Valliere, S., Abate, G., Blazevic, A., Heuertz, R. M., & Hoft, D. F. (2005). Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies. Infection and Immunity, 73(10), 6711–6720.
Desel, C., Dorhoi, A., Bandermann, S., Grode, L., Eisele, B., & Kaufmann, S. H. (2011). Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. The Journal of Infectious Diseases, 204(10), 1573–1584.
Dhiman, R., Indramohan, M., Barnes, P. F., Nayak, R. C., Paidipally, P., Rao, L. V., et al. (2009). IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. Journal of Immunology, 183(10), 6639–6645.
Dhiman, R., Venkatasubramanian, S., Paidipally, P., Barnes, P. F., Tvinnereim, A., & Vankayalapati, R. (2014). Interleukin 22 inhibits intracellular growth of Mycobacterium tuberculosis by enhancing calgranulin a expression. The Journal of Infectious Diseases, 209(4), 578–587.
Divangahi, M., Mostowy, S., Coulombe, F., Kozak, R., Guillot, L., Veyrier, F., et al. (2008). NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. Journal of Immunology, 181(10), 7157–7165.
Domingo-Gonzalez, R., Prince, O., Cooper, A., & Khader, S. A. (2016). Cytokines and chemokines in Mycobacterium tuberculosis infection. Microbiology Spectrum, 4(5). https://doi.org/10.1128/microbiolspec.TBTB2-0018-2016.
du Preez, I., & Loots, D. T. (2013). New sputum metabolite markers implicating adaptations of the host to Mycobacterium tuberculosis, and vice versa. Tuberculosis (Edinburgh, Scotland), 93(3), 330–337.
Encinales, L., Zuniga, J., Granados-Montiel, J., Yunis, M., Granados, J., Almeciga, I., et al. (2010). Humoral immunity in tuberculin skin test anergy and its role in high-risk persons exposed to active tuberculosis. Molecular Immunology, 47(5), 1066–1073.
Fahey, T. J., 3rd, Tracey, K. J., Tekamp-Olson, P., Cousens, L. S., Jones, W. G., Shires, G. T., et al. (1992). Macrophage inflammatory protein 1 modulates macrophage function. Journal of Immunology, 148(9), 2764–2769.
Feng, L., Li, L., Liu, Y., Qiao, D., Li, Q., Fu, X., et al. (2011). B lymphocytes that migrate to tuberculous pleural fluid via the SDF-1/CXCR4 axis actively respond to antigens specific for Mycobacterium tuberculosis. European Journal of Immunology, 41(11), 3261–3269.
Fielding, C. A., McLoughlin, R. M., McLeod, L., Colmont, C. S., Najdovska, M., Grail, D., et al. (2008). IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. Journal of Immunology, 181(3), 2189–2195.
Flynn, J. L., & Chan, J. (2005). What’s good for the host is good for the bug. Trends in Microbiology, 13(3), 98–102.
Flynn, J. L., Chan, J., & Lin, P. L. (2011). Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunology, 4(3), 271–278.
Frieden, T. R., Sterling, T. R., Munsiff, S. S., Watt, C. J., & Dye, C. (2003). Tuberculosis. Lancet, 362(9387), 887–899.
Garner, B., Mellor, H. R., Butters, T. D., Dwek, R. A., & Platt, F. M. (2002). Modulation of THP-1 macrophage and cholesterol-loaded foam cell apolipoprotein E levels by glycosphingolipids. Biochemical and Biophysical Research Communications, 290(5), 1361–1367.
Geijtenbeek, T. B., Van Vliet, S. J., Koppel, E. A., Sanchez-Hernandez, M., Vandenbroucke-Grauls, C. M., Appelmelk, B., et al. (2003). Mycobacteria target DC-SIGN to suppress dendritic cell function. The Journal of Experimental Medicine, 197(1), 7–17.
Gopal, R., Rangel-Moreno, J., Slight, S., Lin, Y., Nawar, H. F., Fallert Junecko, B. A., et al. (2013). Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis. Mucosal Immunology, 6(5), 972–984.
Gordon, S. (2003). Alternative activation of macrophages. Nature Reviews. Immunology, 3(1), 23–35.
Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., & Lambrecht, B. N. (2014). The function of Fcgamma receptors in dendritic cells and macrophages. Nature Reviews. Immunology, 14(2), 94–108.
Hamasur, B., Haile, M., Pawlowski, A., Schroder, U., Kallenius, G., & Svenson, S. B. (2004). A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab’) fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clinical and Experimental Immunology, 138(1), 30–38.
Harris, J., De Haro, S. A., Master, S. S., Keane, J., Roberts, E. A., Delgado, M., et al. (2007). T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity, 27(3), 505–517.
Heitmann, L., Abad Dar, M., Schreiber, T., Erdmann, H., Behrends, J., McKenzie, A. N., et al. (2014). The IL-13/IL-4Ralpha axis is involved in tuberculosis-associated pathology. The Journal of Pathology, 234(3), 338–350.
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., et al. (2000). A toll-like receptor recognizes bacterial DNA. Nature, 408(6813), 740–745.
Hoheisel, G., Izbicki, G., Roth, M., Chan, C. H., Leung, J. C., Reichenberger, F., et al. (1998). Compartmentalization of pro-inflammatory cytokines in tuberculous pleurisy. Respiratory Medicine, 92(1), 14–17.
Hossain, M. M., & Norazmi, M. N. (2013). Pattern recognition receptors and cytokines in Mycobacterium tuberculosis infection--the double-edged sword? BioMed Research International, 2013, 179174.
Hsieh, C. H., Frink, M., Hsieh, Y. C., Kan, W. H., Hsu, J. T., Schwacha, M. G., et al. (2008). The role of MIP-1 alpha in the development of systemic inflammatory response and organ injury following trauma hemorrhage. Journal of Immunology, 181(4), 2806–2812.
Hussain, R., Ansari, A., Talat, N., Hasan, Z., & Dawood, G. (2011). CCL2/MCP-I genotype- phenotype relationship in latent tuberculosis infection. PLoS One, 6(10), e25803.
Huynh, K. K., Joshi, S. A., & Brown, E. J. (2011). A delicate dance: Host response to mycobacteria. Current Opinion in Immunology, 23(4), 464–472.
Jacobs, A. J., Mongkolsapaya, J., Screaton, G. R., McShane, H., & Wilkinson, R. J. (2016). Antibodies and tuberculosis. Tuberculosis (Edinburgh, Scotland), 101, 102–113.
Jones, L. L., & Vignali, D. A. (2011). Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Immunologic Research, 51(1), 5–14.
Joosten, S. A., van Meijgaarden, K. E., Del Nonno, F., Baiocchini, A., Petrone, L., Vanini, V., et al. (2016). Patients with tuberculosis have a dysfunctional circulating B-cell compartment, which normalizes following successful treatment. PLoS Pathogens, 12(6), e1005687.
Kaplan, G., Post, F. A., Moreira, A. L., Wainwright, H., Kreiswirth, B. N., Tanverdi, M., et al. (2003). Mycobacterium tuberculosis growth at the cavity surface: A microenvironment with failed immunity. Infection and Immunity, 71(12), 7099–7108.
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., et al. (2001). Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. The New England Journal of Medicine, 345(15), 1098–1104.
Khader, S. A., Partida-Sanchez, S., Bell, G., Jelley-Gibbs, D. M., Swain, S., Pearl, J. E., et al. (2006). Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. The Journal of Experimental Medicine, 203(7), 1805–1815.
Khader, S. A., Bell, G. K., Pearl, J. E., Fountain, J. J., Rangel-Moreno, J., Cilley, G. E., et al. (2007). IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nature Immunology, 8(4), 369–377.
Khader, S. A., Guglani, L., Rangel-Moreno, J., Gopal, R., Junecko, B. A., Fountain, J. J., et al. (2011). IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. Journal of Immunology, 187(10), 5402–5407.
Kim, M. J., Wainwright, H. C., Locketz, M., Bekker, L. G., Walther, G. B., Dittrich, C., et al. (2010). Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Molecular Medicine, 2(7), 258–274.
Kinjo, Y., Kawakami, K., Uezu, K., Yara, S., Miyagi, K., Koguchi, Y., et al. (2002). Contribution of IL-18 to Th1 response and host defense against infection by Mycobacterium tuberculosis: A comparative study with IL-12p40. Journal of Immunology, 169(1), 323–329.
Kiran, D., Podell, B. K., Chambers, M., & Basaraba, R. J. (2016). Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: A review. Seminars in Immunopathology, 38(2), 167–183.
Kohmo, S., Kijima, T., Mori, M., Minami, T., Namba, Y., Yano, Y., et al. (2012). CXCL12 as a biological marker for the diagnosis of tuberculous pleurisy. Tuberculosis (Edinburgh, Scotland), 92(3), 248–252.
Kolloli, A., & Subbian, S. (2017). Host-directed therapeutic strategies for tuberculosis. Frontiers in Medicine (Lausanne), 4, 171.
Koo, M. S., Manca, C., Yang, G., O’Brien, P., Sung, N., Tsenova, L., et al. (2011). Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS One, 6(2), e17091.
Kozakiewicz, L., Phuah, J., Flynn, J., & Chan, J. (2013). The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Advances in Experimental Medicine and Biology, 783, 225–250.
Kramnik, I., & Beamer, G. (2016). Mouse models of human TB pathology: Roles in the analysis of necrosis and the development of host-directed therapies. Seminars in Immunopathology, 38(2), 221–237.
Krutzik, S. R., Ochoa, M. T., Sieling, P. A., Uematsu, S., Ng, Y. W., Legaspi, A., et al. (2003). Activation and regulation of toll-like receptors 2 and 1 in human leprosy. Nature Medicine, 9(5), 525–532.
Kumar, N. P., Gopinath, V., Sridhar, R., Hanna, L. E., Banurekha, V. V., Jawahar, M. S., et al. (2013). IL-10 dependent suppression of type 1, type 2 and type 17 cytokines in active pulmonary tuberculosis. PLoS One, 8(3), e59572.
Kumar, S. K., Singh, P., & Sinha, S. (2015). Naturally produced opsonizing antibodies restrict the survival of Mycobacterium tuberculosis in human macrophages by augmenting phagosome maturation. Open Biology, 5(12), 150171.
Kumar, N. P., Banurekha, V. V., Nair, D., & Babu, S. (2016). Circulating angiogenic factors as biomarkers of disease severity and bacterial burden in pulmonary tuberculosis. PLoS One, 11(1), e0146318.
Ladel, C. H., Blum, C., Dreher, A., Reifenberg, K., & Kaufmann, S. H. (1995). Protective role of gamma/delta T cells and alpha/beta T cells in tuberculosis. European Journal of Immunology, 25(10), 2877–2881.
Law, K., Weiden, M., Harkin, T., Tchou-Wong, K., Chi, C., & Rom, W. N. (1996). Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine, 153(2), 799–804.
Lin, P. L., & Flynn, J. L. (2010). Understanding latent tuberculosis: A moving target. Journal of Immunology, 185(1), 15–22.
Lin, P. L., Rodgers, M., Smith, L., Bigbee, M., Myers, A., Bigbee, C., et al. (2009). Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infection and Immunity, 77(10), 4631–4642.
Lin, P. L., Rutledge, T., Green, A. M., Bigbee, M., Fuhrman, C., Klein, E., et al. (2012). CD4 T cell depletion exacerbates acute Mycobacterium tuberculosis while reactivation of latent infection is dependent on severity of tissue depletion in cynomolgus macaques. AIDS Research and Human Retroviruses, 28(12), 1693–1702.
Lindenstrom, T., Woodworth, J., Dietrich, J., Aagaard, C., Andersen, P., & Agger, E. M. (2012). Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset. Infection and Immunity, 80(10), 3533–3544.
Lingnau, M., Hoflich, C., Volk, H. D., Sabat, R., & Docke, W. D. (2007). Interleukin-10 enhances the CD14-dependent phagocytosis of bacteria and apoptotic cells by human monocytes. Human Immunology, 68(9), 730–738.
Liu, P. T., Schenk, M., Walker, V. P., Dempsey, P. W., Kanchanapoomi, M., Wheelwright, M., et al. (2009). Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One, 4(6), e5810.
Lockhart, E., Green, A. M., & Flynn, J. L. (2006). IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. Journal of Immunology, 177(7), 4662–4669.
Lugo-Villarino, G., Hudrisier, D., Benard, A., & Neyrolles, O. (2012). Emerging trends in the formation and function of tuberculosis granulomas. Frontiers in Immunology, 3, 405.
Maglione, P. J., Xu, J., & Chan, J. (2007). B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. Journal of Immunology, 178(11), 7222–7234.
Maglione, P. J., Xu, J., Casadevall, A., & Chan, J. (2008). Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. Journal of Immunology, 180(5), 3329–3338.
Marino, S., El-Kebir, M., & Kirschner, D. (2011). A hybrid multi-compartment model of granuloma formation and T cell priming in tuberculosis. Journal of Theoretical Biology, 280(1), 50–62.
Master, S. S., Rampini, S. K., Davis, A. S., Keller, C., Ehlers, S., Springer, B., et al. (2008). Mycobacterium tuberculosis prevents inflammasome activation. Cell Host & Microbe, 3(4), 224–232.
Matthews, K., Wilkinson, K. A., Kalsdorf, B., Roberts, T., Diacon, A., Walzl, G., et al. (2011). Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis. Tuberculosis (Edinburgh, Scotland), 91(6), 587–593.
Mattila, J. T., Ojo, O. O., Kepka-Lenhart, D., Marino, S., Kim, J. H., Eum, S. Y., et al. (2013). Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. Journal of Immunology, 191(2), 773–784.
Mazzarella, G., Bianco, A., Perna, F., D’Auria, D., Grella, E., Moscariello, E., et al. (2003). T lymphocyte phenotypic profile in lung segments affected by cavitary and non-cavitary tuberculosis. Clinical and Experimental Immunology, 132(2), 283–288.
McAleer, J. P., & Kolls, J. K. (2014). Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunological Reviews, 260(1), 129–144.
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O’Garra, A. (2001). Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology, 19, 683–765.
Moser, B., & Loetscher, P. (2001). Lymphocyte traffic control by chemokines. Nature Immunology, 2(2), 123–128.
Nandi, B., & Behar, S. M. (2011). Regulation of neutrophils by interferon-gamma limits lung inflammation during tuberculosis infection. The Journal of Experimental Medicine, 208(11), 2251–2262.
Nigou, J., Zelle-Rieser, C., Gilleron, M., Thurnher, M., & Puzo, G. (2001). Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: Evidence for a negative signal delivered through the mannose receptor. Journal of Immunology, 166(12), 7477–7485.
O’Garra, A., Redford, P. S., McNab, F. W., Bloom, C. I., Wilkinson, R. J., & Berry, M. P. (2013). The immune response in tuberculosis. Annual Review of Immunology, 31, 475–527.
O’Kane, C. M., Boyle, J. J., Horncastle, D. E., Elkington, P. T., & Friedland, J. S. (2007). Monocyte-dependent fibroblast CXCL8 secretion occurs in tuberculosis and limits survival of mycobacteria within macrophages. Journal of Immunology, 178(6), 3767–3776.
O’Leary, S., O’Sullivan, M. P., & Keane, J. (2011). IL-10 blocks phagosome maturation in mycobacterium tuberculosis-infected human macrophages. American Journal of Respiratory Cell and Molecular Biology, 45(1), 172–180.
Oehlers, S. H., Cronan, M. R., Scott, N. R., Thomas, M. I., Okuda, K. S., Walton, E. M., et al. (2015). Interception of host angiogenic signalling limits mycobacterial growth. Nature, 517(7536), 612–615.
Okamoto Yoshida, Y., Umemura, M., Yahagi, A., O’Brien, R. L., Ikuta, K., Kishihara, K., et al. (2010). Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. Journal of Immunology, 184(8), 4414–4422.
Olivares, N., Puig, A., Aguilar, D., Moya, A., Cadiz, A., Otero, O., et al. (2009). Prophylactic effect of administration of human gamma globulins in a mouse model of tuberculosis. Tuberculosis (Edinburgh, Scotland), 89(3), 218–220.
Ordway, D., Henao-Tamayo, M., Harton, M., Palanisamy, G., Troudt, J., Shanley, C., et al. (2007). The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. Journal of Immunology, 179(1), 522–531.
Osherov, N., & Ben-Ami, R. (2016). Modulation of host angiogenesis as a microbial survival strategy and therapeutic target. PLoS Pathogens, 12(4), e1005479.
Pahari, S., Kaur, G., Aqdas, M., Negi, S., Chatterjee, D., Bashir, H., et al. (2017). Bolstering immunity through pattern recognition receptors: A unique approach to control tuberculosis. Frontiers in Immunology, 8, 906.
Palsson-McDermott, E. M., Curtis, A. M., Goel, G., Lauterbach, M. A., Sheedy, F. J., Gleeson, L. E., et al. (2015). Pyruvate kinase M2 regulates Hif-1alpha activity and IL-1beta induction and is a critical determinant of the Warburg effect in LPS-activated macrophages. Cell Metabolism, 21(1), 65–80.
Pandey, A. K., & Sassetti, C. M. (2008). Mycobacterial persistence requires the utilization of host cholesterol. Proceedings of the National Academy of Sciences of the United States of America, 105(11), 4376–4380.
Pandey, A. K., Yang, Y., Jiang, Z., Fortune, S. M., Coulombe, F., Behr, M. A., et al. (2009). NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS Pathogens, 5(7), e1000500.
Philips, J. A., & Ernst, J. D. (2012). Tuberculosis pathogenesis and immunity. Annual Review of Pathology, 7, 353–384.
Quesniaux, V., Fremond, C., Jacobs, M., Parida, S., Nicolle, D., Yeremeev, V., et al. (2004). Toll- like receptor pathways in the immune responses to mycobacteria. Microbes and Infection, 6(10), 946–959.
Rajaram, M. V. S., Arnett, E., Azad, A. K., Guirado, E., Ni, B., Gerberick, A. D., et al. (2017). M. tuberculosis-initiated human mannose receptor signaling regulates macrophage recognition and vesicle trafficking by FcRgamma-chain, Grb2, and SHP-1. Cell Reports, 21(1), 126–140.
Reiling, N., Holscher, C., Fehrenbach, A., Kroger, S., Kirschning, C. J., Goyert, S., et al. (2002). Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. Journal of Immunology, 169(7), 3480–3484.
Rodrigo, T., Cayla, J. A., Garcia de Olalla, P., Galdos-Tanguis, H., Jansa, J. M., Miranda, P., et al. (1997). Characteristics of tuberculosis patients who generate secondary cases. The International Journal of Tuberculosis and Lung Disease, 1(4), 352–357.
Russell, D. G., Cardona, P. J., Kim, M. J., Allain, S., & Altare, F. (2009a). Foamy macrophages and the progression of the human tuberculosis granuloma. Nature Immunology, 10(9), 943–948.
Russell, D. G., Vanderven, B. C., Glennie, S., Mwandumba, H., & Heyderman, R. S. (2009b). The macrophage marches on its phagosome: Dynamic assays of phagosome function. Nature Reviews. Immunology, 9(8), 594–600.
Sakai, H., Okafuji, I., Nishikomori, R., Abe, J., Izawa, K., Kambe, N., et al. (2010). The CD40-CD40L axis and IFN-gamma play critical roles in Langhans giant cell formation. International Immunology, 24(1), 5–15.
Saukkonen, J. J., Bazydlo, B., Thomas, M., Strieter, R. M., Keane, J., & Kornfeld, H. (2002). Beta-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infection and Immunity, 70(4), 1684–1693.
Schlesinger, L. S., Hull, S. R., & Kaufman, T. M. (1994). Binding of the terminal mannosyl units of lipoarabinomannan from a virulent strain of Mycobacterium tuberculosis to human macrophages. Journal of Immunology, 152(8), 4070–4079.
Seiler, P., Aichele, P., Bandermann, S., Hauser, A. E., Lu, B., Gerard, N. P., et al. (2003). Early granuloma formation after aerosol Mycobacterium tuberculosis infection is regulated by neutrophils via CXCR3-signaling chemokines. European Journal of Immunology, 33(10), 2676–2686.
Semenza, G. L. (2010). HIF-1: upstream and downstream of cancer metabolism. Current Opinion in Genetics and Development, 20(1), 51–56.
Shalekoff, S., & Tiemessen, C. T. (2003). Circulating levels of stromal cell-derived factor 1alpha and interleukin 7 in HIV type 1 infection and pulmonary tuberculosis are reciprocally related to CXCR4 expression on peripheral blood leukocytes. AIDS Research and Human Retroviruses, 19(6), 461–468.
Shi, L., Eugenin, E. A., & Subbian, S. (2016). Immunometabolism in tuberculosis. Frontiers in Immunology, 7, 150.
Siveke, J. T., & Hamann, A. (1998). T helper 1 and T helper 2 cells respond differentially to chemokines. Journal of Immunology, 160(2), 550–554.
Stegelmann, F., Bastian, M., Swoboda, K., Bhat, R., Kiessler, V., Krensky, A. M., et al. (2005). Coordinate expression of CC chemokine ligand 5, granulysin, and perforin in CD8+ T cells provides a host defense mechanism against Mycobacterium tuberculosis. Journal of Immunology, 175(11), 7474–7483.
Strzelak, A., Komorowska-Piotrowska, A., & Ziolkowski, J. (2012). [CXCL10/IP-10 as a new biomarker for Mycobacterium tuberculosis infection]. Polski Merkuriusz Lekarski, 33(198), 342–345.
Subbian, S., Tsenova, L., Yang, G., O’Brien, P., Parsons, S., Peixoto, B., et al. (2011). Chronic pulmonary cavitary tuberculosis in rabbits: A failed host immune response. Open Biology, 1(4), 110016.
Suwara, M. I., Green, N. J., Borthwick, L. A., Mann, J., Mayer-Barber, K. D., Barron, L., et al. (2014). IL-1alpha released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts. Mucosal Immunology, 7(3), 684–693.
Tabarsi, P., Marjani, M., Mansouri, N., Farnia, P., Boisson-Dupuis, S., Bustamante, J., et al. (2011). Lethal tuberculosis in a previously healthy adult with IL-12 receptor deficiency. Journal of Clinical Immunology, 31(4), 537–539.
Tan, S., & Russell, D. G. (2015). Trans-species communication in the Mycobacterium tuberculosis-infected macrophage. Immunological Reviews, 264(1), 233–248.
Toossi, Z., & Ellner, J. J. (1998). The role of TGF beta in the pathogenesis of human tuberculosis. Clinical Immunology and Immunopathology, 87(2), 107–114.
Toossi, Z., Gogate, P., Shiratsuchi, H., Young, T., & Ellner, J. J. (1995). Enhanced production of TGF-beta by blood monocytes from patients with active tuberculosis and presence of TGF-beta in tuberculous granulomatous lung lesions. Journal of Immunology, 154(1), 465–473.
Tsenova, L., O’Brien, P., Holloway, J., Peixoto, B., Soteropoulos, P., Fallows, D., et al. (2014). Etanercept exacerbates inflammation and pathology in a rabbit model of active pulmonary tuberculosis. Journal of Interferon & Cytokine Research, 34(9), 716–726.
Uehira, K., Amakawa, R., Ito, T., Tajima, K., Naitoh, S., Ozaki, Y., et al. (2002). Dendritic cells are decreased in blood and accumulated in granuloma in tuberculosis. Clinical Immunology, 105(3), 296–303.
Ulrichs, T., Kosmiadi, G. A., Jörg, S., Pradl, L., Titukhina, M., Mishenko, V., et al. (2005). Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculoma. The Journal of Infectious Diseases, 192(1), 89–97.
Verway, M., Bouttier, M., Wang, T. T., Carrier, M., Calderon, M., An, B. S., et al. (2013). Vitamin D induces interleukin-1beta expression: Paracrine macrophage epithelial signaling controls M. tuberculosis infection. PLoS Pathogens, 9(6), e1003407.
Vesosky, B., Rottinghaus, E. K., Stromberg, P., Turner, J., & Beamer, G. (2010). CCL5 participates in early protection against Mycobacterium tuberculosis. Journal of Leukocyte Biology, 87(6), 1153–1165.
Wallis, R. S., Kyambadde, P., Johnson, J. L., Horter, L., Kittle, R., Pohle, M., et al. (2004). A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV- 1-associated tuberculosis. AIDS, 18(2), 257–264.
Welsh, K. J., Risin, S. A., Actor, J. K., & Hunter, R. L. (2011). Immunopathology of postprimary tuberculosis: Increased T-regulatory cells and DEC-205-positive foamy macrophages in cavitary lesions. Clinical & Developmental Immunology, 2011, 307631.
WHO. (2017). Global tuberculosis report. Geneva: World Health Organization.
Wieland, C. W., van der Windt, G. J., Wiersinga, W. J., Florquin, S., & van der Poll, T. (2008). CD14 contributes to pulmonary inflammation and mortality during murine tuberculosis. Immunology, 125(2), 272–279.
Wozniak, T. M., Ryan, A. A., & Britton, W. J. (2006). Interleukin-23 restores immunity to Mycobacterium tuberculosis infection in IL-12p40-deficient mice and is not required for the development of IL-17-secreting T cell responses. Journal of Immunology, 177(12), 8684–8692.
Zhang, Y., Lathigra, R., Garbe, T., Catty, D., & Young, D. (1991). Genetic analysis of superoxide dismutase, the 23 kilodalton antigen of Mycobacterium tuberculosis. Molecular Microbiology, 5(2), 381–391.
Zhang, Z., Kaptanoglu, L., Tang, Y., Ivancic, D., Rao, S. M., Luster, A., et al. (2004). IP-10-induced recruitment of CXCR3 host T cells is required for small bowel allograft rejection. Gastroenterology, 126(3), 809–818.
Zumla, A., Raviglione, M., Hafner, R., & von Reyn, C. F. (2013). Tuberculosis. The New England Journal of Medicine, 368(8), 745–755.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kolloli, A., Singh, P., Subbian, S. (2018). Granulomatous Response to Mycobacterium tuberculosis Infection. In: Venketaraman, V. (eds) Understanding the Host Immune Response Against Mycobacterium tuberculosis Infection. Springer, Cham. https://doi.org/10.1007/978-3-319-97367-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-97367-8_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-97366-1
Online ISBN: 978-3-319-97367-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)